Payment overview · 2025
General Payments
$899.55
54 reported records · 19 companies
Healthcare provider profile · identity verified
Matthew N. Klain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLAIRSVILLE, PA · NPI 1952367401
Verified facts
What the public records show
CMS Open Payments records show Matthew N. Klain, MD received $899.55 in general payments during 2025 across 54 reported records.
ABBVIE INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 635 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.87 | 23.2% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.39 | 9.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.02 | 7.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.05 | 6.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.14 | 6.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.35 | 6.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.84 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.98 | 4.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.31 | 4.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.77 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.11 | 3.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $29.57 | 3.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.94 | 3.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.83 | 2.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.53 | 2.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.21 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.06 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.37 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.21 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $899.55 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.46 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $136.54 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $88.65 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $60.05 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.35 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.60 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.11 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $12.26 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $11.00 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $11.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 635 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 216 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
635 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
67 | 66 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1072 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 976 | 211 |
| Pantoprazole Sodium | Pantoprazole Sodium | 921 | 208 |
| Furosemide | Furosemide | 830 | 130 |
| Potassium Chloride | Potassium Chloride | 737 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 635 | 150 |
| Eliquis | Apixaban | 635 | 106 |
| Escitalopram Oxalate | Escitalopram Oxalate | 604 | 108 |
| Lisinopril | Lisinopril | 520 | 125 |
| Gabapentin | Gabapentin | 484 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 459 | 96 |
| Losartan Potassium | Losartan Potassium | 450 | 100 |
| Tramadol Hcl | Tramadol Hcl | 432 | 121 |
| Donepezil Hcl | Donepezil Hcl | 426 | 64 |
| Trazodone Hcl | Trazodone Hcl | 404 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 368 | 90 |
| Omeprazole | Omeprazole | 361 | 83 |
| Metformin Hcl | Metformin Hcl | 356 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 345 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 321 | 81 |
| Buspirone Hcl | Buspirone Hcl | 312 | 60 |
| Azithromycin | Azithromycin | 308 | 223 |
| Sertraline Hcl | Sertraline Hcl | 304 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 277 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 261 | 54 |
| Famotidine | Famotidine | 255 | 54 |
| Carvedilol | Carvedilol | 250 | 53 |
| Xarelto | Rivaroxaban | 229 | 43 |
| Allopurinol | Allopurinol | 216 | 45 |
| Jardiance | Empagliflozin | 216 | 47 |
| Memantine Hcl | Memantine Hcl | 213 | 29 |
| Simvastatin | Simvastatin | 212 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 201 | 58 |
| Methylprednisolone | Methylprednisolone | 198 | 167 |
| Meloxicam | Meloxicam | 193 | 63 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 193 | 141 |
| Montelukast Sodium | Montelukast Sodium | 183 | 35 |
| Glimepiride | Glimepiride | 181 | 47 |
| Warfarin Sodium | Warfarin Sodium | 181 | 20 |
| Finasteride | Finasteride | 177 | 37 |
| Mirtazapine | Mirtazapine | 175 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 158 | 77 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 158 | 52 |
| Ozempic | Semaglutide | 151 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 149 | 22 |
| Levetiracetam | Levetiracetam | 145 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 134 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 35 |
| Bupropion Xl | Bupropion Hcl | 125 | 35 |
| Trulicity | Dulaglutide | 120 | 26 |
| Spironolactone | Spironolactone | 117 | 22 |
| Fentanyl | Fentanyl | 115 | 18 |
| Aripiprazole | Aripiprazole | 112 | 16 |
| Risperidone | Risperidone | 110 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 106 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 40 |
| Lorazepam | Lorazepam | 100 | 38 |
| Valsartan | Valsartan | 99 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 97 | 25 |
| Pregabalin | Pregabalin | 97 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 93 | 20 |
| Bumetanide | Bumetanide | 91 | 17 |
| Latanoprost | Latanoprost | 91 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 28 |
| Synthroid | Levothyroxine Sodium | 91 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 53 |
| Prednisone | Prednisone | 85 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 83 | 16 |
| Cephalexin | Cephalexin | 83 | 54 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 15 |
| Fluconazole | Fluconazole | 81 | 55 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 79 | 15 |
| Baclofen | Baclofen | 77 | 22 |
| Atenolol | Atenolol | 76 | 22 |
| Meclizine Hcl | Meclizine Hcl | 76 | 33 |
| Sucralfate | Sucralfate | 75 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | 11 |
| Nystatin | Nystatin | 74 | 40 |
| Bupropion Hcl Sr | Bupropion Hcl | 72 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 13 |
| Ibuprofen | Ibuprofen | 71 | 23 |
| Irbesartan | Irbesartan | 70 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 13 |
| Ondansetron Odt | Ondansetron | 69 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 54 |
| Paxlovid | Nirmatrelvir/Ritonavir | 67 | 66 |
| Ezetimibe | Ezetimibe | 64 | 16 |
| Novolog Flexpen | Insulin Aspart | 63 | suppressed |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Mounjaro | Tirzepatide | 62 | 15 |
| Alprazolam | Alprazolam | 60 | 17 |
| Hydrocortisone | Hydrocortisone | 59 | 14 |
| Metformin Hcl Er | Metformin Hcl | 59 | 16 |
| Benazepril Hcl | Benazepril Hcl | 57 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 39 |
| Glipizide | Glipizide | 56 | 12 |
| Celecoxib | Celecoxib | 55 | 13 |
| Digoxin | Digoxin | 54 | 14 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Clonazepam | Clonazepam | 53 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 16 |
| Lamotrigine | Lamotrigine | 51 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 14 |
| Loperamide | Loperamide Hcl | 50 | 28 |
| Permethrin | Permethrin | 49 | 32 |
| Mupirocin | Mupirocin | 48 | 36 |
| Amoxicillin | Amoxicillin | 47 | 27 |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 13 |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Myrbetriq | Mirabegron | 45 | 16 |
| Primidone | Primidone | 44 | 12 |
| Clonidine Hcl | Clonidine Hcl | 43 | 14 |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 16 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Anastrozole | Anastrozole | 40 | suppressed |
| Colchicine | Colchicine | 40 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 20 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | 12 |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Mesalamine Dr | Mesalamine | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Sulfasalazine | Sulfasalazine | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Desoximetasone | Desoximetasone | 25 | 19 |
| Linzess | Linaclotide | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 17 |
| Acyclovir | Acyclovir | 19 | 11 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Pentasa | Mesalamine | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Perphenazine | Perphenazine | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methazolamide | Methazolamide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Teriflunomide | Teriflunomide | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vancomycin Hcl-0.9% Nacl | Vancomycin/0.9 % Sod Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $899.55 · 54 records | ABBVIE INC. | AVYCAZ, CAPLYTA, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GLASSIA, IBSRELA, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, Ozempic, QULIPTA, REXULTI, Rybelsus, TEFLARO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error